Tumor Necrosis Factor (TNF): The Central Molecule in Inflammation and Immune Regulation

The Molecular Structure and Signaling Mechanisms of TNF
Tumor necrosis factor (TNF) is a type II transmembrane protein composed of 233 amino acids, which releases a 157-amino-acid soluble cytokine upon cleavage by the metalloproteinase TACE (ADAM17). Structurally, TNF exists as a stable homotrimer, with each monomer featuring a β-sheet "sandwich" structure stabilized by hydrophobic interactions. X-ray crystallography reveals that the TNF trimer induces the formation of a trimeric conformation in TNFR1 or TNFR2 upon receptor binding, triggering downstream signaling. TNF has two biologically active forms: transmembrane TNF (mTNF), which primarily mediates local cell-to-cell signaling, and soluble TNF (sTNF), which participates in systemic inflammatory responses. TNF receptors are divided into two types: TNFR1 (p55), widely expressed in various cell types and containing a death domain (DD) that activates apoptosis and inflammatory pathways; and TNFR2 (p75), mainly expressed in immune cells and endothelial cells, involved in tissue repair and immune regulation. Upon binding to TNFR1, TNF activates two major pathways through adaptor proteins such as TRADD, RIP1, and TRAF2: the NF-κB pathway promotes inflammatory factor expression and cell survival, while the FADD-caspase8 pathway induces apoptosis. Recent studies have identified a "switch" phenomenon in TNF signaling, where low concentrations primarily activate NF-κB to promote cell survival, while high concentrations tend to induce apoptosis. This dose-dependent effect provides new insights into the dual functions of TNF.
 

 

  
Core Role in Inflammatory Responses
TNF is a key initiator and regulator of inflammatory responses, playing a central role in various acute and chronic inflammatory diseases. When pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs) are recognized by pattern recognition receptors, macrophages and dendritic cells rapidly secrete TNF, initiating an inflammatory cascade. TNF upregulates the expression of endothelial adhesion molecules (e.g., ICAM-1, VCAM-1), promoting leukocyte rolling, adhesion, and transendothelial migration, leading to cellular infiltration at inflammatory sites. At the molecular level, TNF stimulates the production of various pro-inflammatory cytokines (e.g., IL-1, IL-6) and chemokines (e.g., IL-8, MCP-1), while inducing the expression of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), amplifying inflammatory signals. Notably, TNF exhibits a time-dependent functional shift in inflammatory responses: promoting inflammation initiation in the early stages and participating in inflammation resolution and tissue repair in later stages. In rheumatoid arthritis (RA), TNF stimulates synovial fibroblasts to produce matrix metalloproteinases (MMPs), leading to cartilage destruction and bone erosion. In inflammatory bowel disease (IBD), TNF increases intestinal epithelial permeability, disrupting mucosal barrier function. Animal model studies show that TNF gene knockout or antibody neutralization can significantly alleviate pathological damage in various inflammatory diseases but may also impair host defense capabilities. This balance underscores the need for precise modulation in therapeutic interventions.
  
Pathological Mechanisms in Autoimmune Diseases
TNF plays a complex and critical role in the pathogenesis of autoimmune diseases, with its aberrant expression closely linked to the activity of multiple autoimmune conditions. In rheumatoid arthritis (RA), TNF concentrations in joint synovial fluid can be up to 100 times higher than in healthy individuals, activating osteoclasts to cause bone erosion and inhibiting chondrocyte synthesis of proteoglycans. Genome-wide association studies (GWAS) have identified single nucleotide polymorphisms (SNPs) in the TNF gene promoter region associated with RA susceptibility, particularly the TNF-308G>A polymorphism, which increases TNF transcriptional activity. In ankylosing spondylitis (AS), elevated mTNF expression in T cells and macrophages promotes disease progression through TNFR2-mediated activation of the IL-23/IL-17 axis. In inflammatory bowel disease (IBD), TNF upregulates MMP-3 expression in intestinal myofibroblasts, disrupting collagen networks, while suppressing the expression of epithelial tight junction proteins (e.g., ZO-1, occludin), exacerbating intestinal barrier dysfunction. In systemic lupus erythematosus (SLE), serum TNF levels correlate positively with disease activity indices (SLEDAI). Interestingly, however, TNF may also exert protective effects in certain SLE models, a paradoxical effect likely related to disease stage and target organ differences. In multiple sclerosis (MS), TNF contributes to central nervous system inflammation by disrupting the blood-brain barrier and activating microglia. However, anti-TNF therapy unexpectedly worsened symptoms in clinical trials, highlighting the complex spatiotemporal specificity of TNF in neuroinflammation.
  
Clinical Applications and Developments in Anti-TNF Therapy
Anti-TNF therapy has become a milestone treatment for various autoimmune diseases. Since the approval of the first humanized anti-TNF monoclonal antibody, infliximab, in 1998, multiple biologics with diverse mechanisms of action have been developed. Current clinically used anti-TNF drugs can be divided into three categories: monoclonal antibodies (infliximab, adalimumab, golimumab), receptor fusion proteins (etanercept), and pegylated Fab fragments (certolizumab pegol). These drugs exhibit significant differences in pharmacokinetics and pharmacodynamics: IgG1-type monoclonal antibodies (e.g., adalimumab) have a half-life of approximately 2 weeks and can activate complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC), while etanercept, as a TNFR2-Fc fusion protein, has a shorter half-life of 3-5 days and primarily neutralizes soluble TNF. Clinical studies show that anti-TNF therapy achieves ACR50 response rates of 50-60% in RA patients, significantly delaying radiographic progression. In Crohn’s disease, it induces clinical remission in 60-70% of patients and promotes mucosal healing. However, approximately 30-40% of patients experience primary or secondary failure due to mechanisms such as anti-drug antibody production, activation of alternative inflammatory pathways, and epigenetic remodeling. To overcome these limitations, next-generation anti-TNF strategies are under development: bispecific antibodies targeting TNF and IL-17/IL-23, nanobodies with improved tissue penetration, and prodrug-type antibodies selectively activated in inflammatory microenvironments. In personalized medicine, TNF drug concentration monitoring and anti-drug antibody detection-guided dose optimization can improve clinical response rates by 15-20%.
  
Dual Roles in Infection Immunity and Tumor Surveillance
TNF exhibits a complex and nuanced balance of roles in infection defense and tumor immune surveillance, with its functions highly dependent on microenvironmental context and temporal dynamics. In bacterial infections, TNF enhances bactericidal activity by activating macrophages and neutrophils and promotes granuloma formation to limit pathogen spread. However, excessive production may lead to septic shock. Studies on Mycobacterium tuberculosis infection are particularly noteworthy, as anti-TNF therapy increases the risk of latent tuberculosis reactivation by 5-10 times, underscoring TNF’s critical role in maintaining granuloma integrity. In viral infections, TNF limits viral replication by inducing apoptosis, but certain viruses (e.g., EBV, HSV) have evolved mechanisms to evade TNF signaling. Tumor biology research reveals TNF’s dual effects: at physiological levels, it exerts surveillance functions by activating cytotoxic T cells and promoting tumor vascular normalization, while chronic overproduction creates a pro-tumor inflammatory microenvironment. TNF knockout mice show increased spontaneous tumor rates, while some overexpression models exhibit tumor-promoting effects, reflecting the spatiotemporal specificity of TNF’s actions. Clinical observations indicate that anti-TNF therapy may slightly increase lymphoma risk (standardized incidence ratio [SIR] = 2-3), but its impact on solid tumor risk remains unclear. Notably, locally high concentrations of TNF (e.g., isolated limb perfusion) can disrupt tumor vasculature, a property exploited in treating limb melanoma and sarcoma. New findings in the era of immunotherapy reveal that TNF modulates PD-L1 expression and Treg function, influencing checkpoint inhibitor efficacy, which provides a theoretical basis for combination therapy strategies.
  
Future Research Directions and Novel Therapeutic Strategies
The field of TNF research is advancing toward precision, minimally invasive, and intelligent approaches, with several frontier breakthroughs poised to reshape treatment paradigms. Single-cell multi-omics technologies reveal that TNF from different cellular sources has distinct functional characteristics: T cell-derived TNF primarily participates in immune synapse formation, while myeloid-derived TNF preferentially activates tissue remodeling. Based on this, next-generation cell-specific TNF modulation strategies are under development, such as cell-selective siRNA delivery systems targeting TNF mRNA. Epigenetic studies show that the DNA methylation and histone modification states of the TNF locus determine its expression threshold, offering epigenetic biomarkers for predicting treatment responses. In nanomedicine, pH-responsive TNF inhibitors selectively activated in acidic inflammatory microenvironments reduce systemic immunosuppression, while gold nanoparticle-conjugated TNF antibodies enable photothermal combination therapy, demonstrating enhanced efficacy in arthritis models. Bifunctional molecule designs are becoming increasingly sophisticated, such as TNF/IL-17 dual-targeting nanobodies that simultaneously block pro-inflammatory and Th17 pathways, outperforming monotherapy in psoriasis models. Gene editing technologies like CRISPR-Cas9 are used to create TNF signaling reporter cell lines for high-throughput drug screening. Clinical translation is expanding into emerging areas: neuroinflammation in Alzheimer’s disease, chronic low-grade inflammation in metabolic syndrome, and aberrant repair in fibrotic diseases. Over the next five years, an estimated 10-15 novel TNF modulators—including allosteric inhibitors, PROTAC degraders, and gene silencing therapies—are expected to enter clinical research. Combined with AI-driven personalized dosing regimens, these advances will usher in a new era of precision medicine for inflammatory diseases.
 
Click on the product catalog numbers below to access detailed information on our official website.
 
Product Information

S0B3503	TNF RI Recombinant Rabbit mAb (SDT-1656-128-2)	Host : Rabbit Conjugation : Unconjugated
S0B3499	TNF RI Recombinant Rabbit mAb (SDT-1656-155-2)	Host : Rabbit Conjugation : Unconjugated
S0B3502	TNF RI Recombinant Rabbit mAb (SDT-1656-128)	Host : Rabbit Conjugation : Unconjugated
S0B3501	TNF RI Recombinant Rabbit mAb (SDT-1656-145)	Host : Rabbit Conjugation : Unconjugated
S0B3500	TNF RI Recombinant Rabbit mAb (SDT-1656-131)	Host : Rabbit Conjugation : Unconjugated
S0B3498	TNF RI Recombinant Rabbit mAb (SDT-1656-155)	Host : Rabbit Conjugation : Unconjugated
UA011247	PE-Labeled BCMA/TNFRSF17 His Tag Protein, Human	Host : Human Expression System : HEK293 Conjugation : PE
UA011246	Alexa Fluor 647-Labeled BCMA/TNFRSF17 His Tag Protein, Human	Host : Human Expression System : HEK293 Conjugation : Alexa Fluor® 647
UA040173	TNF-α Protein, Mouse	Host : Mouse Expression System : E.coli Conjugation : Unconjugated
UA040005	TNF-α Protein, Human	Host : Human Expression System : CHO Conjugation : Unconjugated

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.